{
    "clinical_study": {
        "@rank": "163285", 
        "acronym": "SBP", 
        "arm_group": [
            {
                "arm_group_label": "rifaximin", 
                "arm_group_type": "Experimental", 
                "description": "Arm 1: 50 patients will be treated with 1200 mg of rifaximin daily for 6 months."
            }, 
            {
                "arm_group_label": "norfloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm 2: 50 patients will be treated with 400 mg of norfloxacin daily for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for\n      secondary  prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis\n      and ascites."
        }, 
        "brief_title": "Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Spontaneous Bacterial Peritonitis", 
            "Ascites", 
            "Liver Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ascites", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Peritonitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be carried out on 100 patients with liver cirrhosis and ascites who will be\n      enrolled from Tanta University, Tropical Medicine Department in the period between January\n      2014  to 6 months. The  selected  patients  will be  randomly  assigned  to  receive 400 mg\n      of norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups :\n\n      Group  1 :  50 patients will be treated with 1200 mg of rifaximin daily. Group 2 :  50\n      patients will be treated with 400 mg of norfloxacin daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previous episode of SBP\n\n          -  Total protein in the ascitic fluid below or equal to 1.5 g/dL\n\n        Exclusion Criteria:\n\n          -  Allergy  to quinolones\n\n          -  Antibiotic therapy in the 2 weeks preceding inclusion\n\n          -  Recent ( within  the  previous  2 weeks)  episode  of  digestive hemorrhage\n\n          -  Hepatocellular  carcinoma  or  other neoplasias able to shorten life expectancy\n\n          -  Pregnant and lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120196", 
            "org_study_id": "Asem Ahmed Elfert"
        }, 
        "intervention": [
            {
                "arm_group_label": "rifaximin", 
                "description": "rifaximin 1200 mg daily versus norfloxacin 400  mg once daily", 
                "intervention_name": "Rifaximin", 
                "intervention_type": "Drug", 
                "other_name": "Gastrobiotic, Trencedia"
            }, 
            {
                "arm_group_label": "norfloxacin", 
                "description": "FDA approved:400mg once daily", 
                "intervention_name": "Norfloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Epinor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Norfloxacin", 
                "Rifaximin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 18, 2014", 
        "location": {
            "contact": {
                "email": "Sherif_tropical@yahoo.com", 
                "last_name": "Sherief Abd-Elsalam", 
                "phone": "00201000040794"
            }, 
            "facility": {
                "address": {
                    "city": "Tanta", 
                    "country": "Egypt"
                }, 
                "name": "Tanta university hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis", 
        "overall_contact": {
            "email": "Sheif_tropical@yahoo.com", 
            "last_name": "Sherief M. Abd-Elsalam, Lecturer", 
            "phone": "00201000040794"
        }, 
        "overall_official": {
            "affiliation": "TUH", 
            "last_name": "Asem A Elfert", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with recurrence of SBP", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120196"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tanta University", 
            "investigator_full_name": "Sherief Abd-Elsalam", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Tanta University", 
        "sponsors": {
            "collaborator": {
                "agency": "Tanta University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sherief Abd-Elsalam", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}